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Background: Acute myeloid leukemia presenting the MYST3-CREBBP fusion gene is a rare
subgroup associated with hemophagocytosis in early infancy and monocytic differentiation.
The  aim of this study was to deﬁne the relevant molecular cytogenetic characteristics of a
unique series of early infancy acute myeloid leukemia cases (≤24 months old), based on the
presence of hemophagocytosis by blast cells at diagnosis.
Methods: A series of 266 infant cases of acute myeloid leukemia was the reference cohort for
the  present analysis. Acute myeloid leukemia cases with hemophagocytosis by blast cells
were  reviewed to investigate the presence of the MYST3-CREBBP fusion gene by ﬂuorescence
in  situ hybridization (FISH) and reverse transcription polymerase chain reaction.
Results: Eleven cases with hemophagocytosis were identiﬁed with hemophagocytic lympho-
histiocytosis being ruled out. Six cases were classiﬁed as myelomonocytic leukemia, three as
AML-M7 and two as AML-M2. In ﬁve cases, the presence of the MYST3-CREBBP fusion gene
identiﬁed by molecular cytogenetics was conﬁrmed by ﬂuorescence in situ hybridization.
All  patients received treatment according to the Berlin–Frankfürt–Münster acute myeloid
leukemia protocols and only one out of the ﬁve patients with the MYST3-CREBBP fusion
gene is still alive.
Conclusions: Our ﬁndings demonstrate that the presence of hemophagocytosis in acute
myeloid  leukemia was not exclusively associated to the MYST3-CREBBP fusion gene.
Improvements in molecular cytogenetics may help to elucidate more complex chromosomal
rearrangements in infants with acute myeloid leukemia and hemophagocytosis.©  2016 Associac¸a˜o Bra
by  Elsevier Editora Lt
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Introduction
Distinct cytogenetic subgroups of acute myeloid leukemia
(AML) have been associated with age-speciﬁc frequencies
and the incidence of unbalanced aberrations; in particu-
lar complex karyotypes increase sharply with age.1 AML
presenting the reciprocal translocation (8;16)(p11;p13) that
generates the MYST3-CREBBP (former named as MOZ-CBP)
fusion gene is mostly observed in adult patients.2 The fusion
of the MYST3 and CREBBP genes occurs when both show
histone acetyltransferase activities leading to the activa-
tion of several targets involved in transcriptional regulation
and cell cycle control.2–4 The evidence of AML  with the
MYST3-CREBBP fusion gene in children was reported by the
International Berlin–Frankfurt–Munster (I-BFM) study group.5
Sixty-two pediatric AML  were identiﬁed in which karyotype
records revealed t(8;16)(p11;p13) in the AML  observed at an
early age, monocyte differentiation [French–American–British
classiﬁcation (FAB) AML-M5] and presence of hemophagocy-
tosis; all of which are associated with very poor outcomes.5
Furthermore, the MYST3-CREBBP fusion gene associated with
disseminated intravascular coagulation and high mortality
rates was observed in a series of French AML  patients.6
These particular clinical, cytological, cytogenetic, and molec-
ular characteristics of AML  with MYST3-CREBBP led to the
suggestion of a unique category in the World Health Orga-
nization (WHO) classiﬁcation due to the poor prognosis.7
Among the clinical spectrum conditions, hemophagocytic
lymphohistiocytosis (HLH) should be included as differen-
tial diagnosis. However, HLH presents phagocyte activation
caused by immune disorders that compromise T cell/natural
killer cells and the normal monocyte-macrophage lineage.8
An accurate case identiﬁcation requires the evaluation of
morphological, cytogenetic and molecular features follow-
ing correlation of obtained parameters, including serological
tests. In this study, the availability of a unique series of early
onset AML  cases prompted us to search for AML-MYST3-
CREBBP cases and to deﬁne relevant molecular cytogenetic
characteristics.
Methods
Subjects
A series of 266 infant AML  (i-AML) cases enrolled in the
Brazilian Collaborative Study Group of Infant Acute Leukemia
(BCSGIAL) from 2003 to 2012 is the reference cohort and subject
for the present analysis.9 The selection criteria were infants
(≤24 months old) with a diagnosis of AML  and the presence
of hemophagocytosis by leukemic blasts (Figure 1). Addition-
ally, 48 i-AML cases without the hemophagocytic feature in the
diagnostic samples were randomly selected to compare with
i-AML cases with hemophagocytosis by blast cells.
Hemophagocytosis was deﬁned as the presence of phago-
cytosis of red cells, lymphocytes and/or platelets only by blast
cells. The morphological ﬁndings were discussed by physi-
cians (RMB, TCCF, BF, IMQM)  and cytologists (EPN, MSPO);
clinical and laboratorial data were checked in each case
for the consistency of inclusion criteria. Gender, age, white 2 0 1 6;3  8(4):291–297
blood cell count (WBC), hemoglobin levels, platelet count,
central nervous system (CNS) involvement, chloroma and
cutaneous leukemia, FAB classiﬁcation as well as the pres-
ence of hemophagocytosis by leukemic blasts were carefully
reviewed. Exclusion criteria included secondary AML, down’s
syndrome, HLH and/or hemophagocytic syndrome associated
with immune disorders and unexplained fever. Frozen sam-
ples from bone marrow (BM) aspirates, peripheral blood and
smears of i-AML cases were selected for further cytogenetic
and molecular studies according to the availability of good
biological material.
All children were treated out of clinical trials, but following
international AML protocols.
Characterization  of  leukemia  cells
Leukemia classiﬁcation of AML was based on criteria pub-
lished by the WHO.7 The diagnosis of AML-M7 was based
on the presence of CD41/CD61 and CD42 markers on blast
cells identiﬁed by immunophenotyping. Karyotypes of BM
aspirates were tested before any chemotherapy treatment.
Chromosomes were identiﬁed and analyzed as recommended
by the International System of Human Cytogenetic Nomen-
clature (ISCN) 2005.10
Reverse  transcription  polymerase  chain  reaction
Total RNA from BM mononuclear cells at the time of diag-
nosis was puriﬁed using the TRIzol reagent according to the
manufacturer’s instructions (Gibco/BRL, Life Technologies, CA,
USA). Brieﬂy, 2 g of total RNA was reverse-transcribed using
the First-Strand cDNA Synthesis KitTM (Amersham Pharmacia
Biotech Inc., NJ, USA). The integrity of cDNA was examined by
amplifying a fragment of the GAPDH gene using previously
described primers and cDNA was used as templates in sub-
sequent polymerase chain reaction (PCR) assays. All cases
were investigated for the presence of the RUNX1-RUNX1T1,
CBFˇ-MYH11, BCR-ABL1, MLL-AFF1 and MLL-MLLT3 fusion
genes.11–12
Detection of the MYST3-CREBBP and reverse CREBBP-MYST3
fusion transcripts were conducted as described elsewhere.13
Single PCR reactions to detect MYST3-CREBBP fusion trans-
cripts type I (MYST3 exon 16-CREBBP exon 3) and type II (MYST3
exon 16-CREBBP exon 4), as well as the type I CREBBP-MYST3
fusion transcript (CREBBP exon 2-MYST3 exon 17) were per-
formed using the primers listed in Table 1. A semi-nested
reaction, adapted from Schmidt et al., was required to detect
type I transcripts.13 Samples from conﬁrmed AML  cases with
MYST3-CREBBP were added as positive controls for type I
transcripts. PCR products for MYST3-CREBBP transcripts (type
I-II) were separated by electrophoresis in 1.5% agarose gel
and subsequently puriﬁed using NucleoSpin Gel and PCR
Clean-up kits (Macherey-Nagel, VWR  International, Oslo, Nor-
way). Amplicons were mixed with the Big Dye terminatorand sequenced in an ABI 3130xl Genetic Analyzer (Applied
Biosystems).
The identiﬁcation of somatic mutations in KRAS, FLT3 and
c-KIT genes were performed by direct sequencing.14–16
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Figure 1 – Morphology of AML-M4 with hemophagocytosis by blast cells. Bone marrow aspiration stained by
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luorescence  in  situ  hybridization
luorescence in situ hybridization (FISH) for the MLL rear-
angements was performed at the time of diagnosis with
resh biological material using a commercial LSI MLL Dual
olor, Break Apart Rearrangement probe (Cytocell Ltd.,
ambridge, UK) according to the manufacturer’s instruc-
ions. The MYST3-CREBBP FISH was performed in interphase
uclei prepared from frozen viable cells of available cases
sing bacteria-derived artiﬁcial chromosome (BAC). These
lones were retrieved from the human genome high reso-
ution BAC re-arrayed clone set available in a web format
http://bacpac.chori.org) and selected according to physical
nd genetic mapping data reported on Ensembl Browser web-
ite (http://www.ensembl.org). DNA was extracted and probes
ere labeled and hybridized by Blue Genome (Cambridge,
K), with Spectrum Orange or Spectrum Green and validated
s a FISH probe set on normal controls. The clones used
ere RP11-231D20 (chr8:42184655-42188062) and RP11-108L9
chr8:41832025-41864392) ﬂanking the MYST3 gene (orange)
nd RP11-387O21 (chr16:3918191-4104380) and RP11-461A8
chr16:3663996-3693579) ﬂanking the CREBBP gene (green).
rocedures were performed according to the manufacturer’s
nstructions. The ﬁrst step was FISH mapping of clones
n normal cells from healthy blood donors in order to
onﬁrm their chromosomal location. Cut-off values were cal-
ulated as 6 ± 3% of fusion gene signals in 100–300 interphase
uclei.
Table 1 – Sequences of the primers used for reverse transcriptio
Designation Sequence (from
MOZ3558F GAGGCCAATGCCAAG
CBP1201R GTTGCAATTGCTTGT
MOZ3536F CCTTTTGAAGATTCT
CBP404R CCTCGTAGAAGCTCC
CBP96F CGCTCGCTCCTCTCC
MOZ3953R TGGAAACGATGGGCT
CBP174F GGGCTGTTTTCGCGA
MOZ3844R GGCTCTTGCCTTTGGith phagocytosis of red cells and lymphocytes.
Ethical  considerations
Treatment was approved by local laws and regulations as well
as by the Institutional Review Boards of each participating
center. Medical informed consent was obtained in accordance
with the Declaration of Helsinki. This study was approved by
the Research Ethics Committee at the Instituto Nacional de
Câncer in Rio de Janeiro, Brazil (CEP/CAEE: 186.688).
Results
The clinical-demographic characteristics of the eleven cases
that fulﬁlled the selection criteria are shown in Table 2.
All patients presented hepatosplenomegaly and three were
reported to have chloroma and one CNS disease. The major-
ity of the patients were male (72.7%) with a median age
of 12 months (range: 0–23 months). The WBC  count varied
from 5.7 to 111.1 × 109/L with a median of 35.9 × 109/L; six
cases were diagnosed as myelomonocytic leukemia (M4/M5),
three cases as AML-M7 and two as AML-M2. Serological tests
for viral infections (Epstein–Barr virus, parvovirus B19 and
human immunodeﬁciency virus) and coagulation examina-
tions were within normal ranges. No infections triggering HLH
were found in any of the eleven cases.
Using the selected BAC clones of the MYST3-CREBBP
fusion gene, three types of hybridization patterns were
observed (Figure 2). The ﬁrst, separated signals of the
n polymerase chain reaction.
 5′ to 3′) Position
ATTAGAAC MOZ exon 16
GTGGGTAC CBP exon 5
GACTCCG MOZ exon 16
GACAGTT CBP exon 3
CTCGCAG CBP exon 2
CAATGACGC MOZ exon 17
GCAGGTG CBP exon 2
GCCATCC MOZ exon 17
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Table 2 – Demographic and clinical characteristics of selected i-AML cases.
Case Age (Mo.) Gender Clinical features Hb (g/dL) WBC (×109/L) Plat count
(×109/L)
Hemoph* FAB Conclusion Outcome
1 12 F Hepatosplenomegaly 5.68 111.1 40.0 + M4 AML-M4
MYST3-CREBPP
Deceased
2 11 M Hepatosplenomegaly 4.0 25.4 26.0 + M5 AML-M5 Alive
3 <1 F Hepatosplenomegaly
Chloroma
10.7  8.6 29.0 + M4 AML-M4
MYST3-CREBPP
Deceased
4 12 M Hepatosplenomegaly 4.2 36.8 35.0 + M2 AML-M2
MYST3-CREBPP
Alive
5 18 M Hepatosplenomegaly
Chloroma
7.0  5.7 3.0 +/− M5 AML-M5
MYST3-CREBPP
Deceased
6 23 M Hepatosplenomegaly 4.6 42.4 57.0 +/− M7 AML-M7
MYST3-CREBPP
Alive
7 10 M Hepatosplenomegaly
Chloroma
10.7  35.0 229.0 + M2 AML-M2 Alive
8 13 M Hepatosplenomegaly 6.2 61.6 45.0 + M5 AML-M5 Alive
9 22 M Hepatosplenomegaly
CNSPOS
5.0 25.9 31.0 + M7 AML-M7 Deceased
10 12 M Hepatosplenomegaly 5.5 45.0 100.0 + M5 AML-M5 Deceased
11 11 F Hepatosplenomegaly 7.0 8.5 20.0 + M7 AML-M7 Deceased
F: female; M: male; (*), Hemoph: hemophagocytosis (range: 5–27% blasts with phagocytosis); Hb: hemoglobin concentration; i-AML: infant acute
iﬁcatmyeloid leukemia; Mo: months; FAB: French–American–British class
blood cell count.
probe combinations RP11-231D20/RP11-108L9 and RP11-
387O21/RP11-461A8 on chromosomes 8 and 16 respectively,
were observed as four different signals: two red and two
green distinct signals consistent with normal chromosomes
(Figure 2A). Second, a single fusion pattern was observed
(one fusion, one red and one green) considered as a random
co-localized signal (Figure 2B). Lastly, a dual fusion signal was
found in 15–37% of the interphase nuclei analyzed which was
consistent with a breakpoint in MYST3 and CREBBP (Figure 2C).
The RT-PCR technique was performed in 55 samples; seven
samples were from i-AML with hemophagocytosis (Table 3)
and 48 samples from i-AML without hemophagocytosis. The
RT-PCR pattern was different to expected (∼1000 bp) in one
case, with a ∼900 bp product observed (#1). In ﬁve cases (#3,
#5, #6, #7 and #10), RT-PCR was negative for type I and II
transcripts. Despite accurate mapping of the translocation
breakpoints, attempts to amplify the transcripts, as well as
the CREBPP-MYST3 were not successful. In four cases (#2,
#4, #8 and #9), RT-PCR was not performed due to lack of
Figure 2 – FISH pattern of MYST3-CREBBP probes. Three types of 
green signals (A); a single fusion pattern, with one red and one gion; NOS: not otherwise speciﬁed; Plat: platelet count; WBC: white
suitable biological material. Discrepancies were observed in
three cases (#3, #5 and #6) in which dual fusion signals were
found in 15–18% and 34% of the interphase nuclei analyzed
and RT-PCR results were negative. In all the i-AML cases
without hemophagocytosis, the RT-PCR results were negative
(Figure 3).
As shown in Table 3, the diagnosis of the MYST3-
CREBBP fusion gene was based on the FISH results only
or combined with the RT-PCR results. Five cases were
diagnosed as AML-MYST3-CREBBP and clinical laboratorial fea-
tures are summarized: they presented hepatosplenomegaly,
skin lesions and/or localized chloroma; hematological tests
revealed FAB AML-M2, M4,  M5, or M7; the presence of
hemophagocytosis by blast cells varied from 5 to 25%. The
immunophenotyping proﬁle showed cells positive for the
CD34, CD33/CD13/CD14/CD11b/CD14/CD15, CD64, CD56 anti-
gens; in three patients, the blast cells were positive for
CD61/CD41a/CD42b/CD56; karyotyping was successful in four
cases; one case (#1) revealed a 46, XX, der (16), t(16;?) (p13;?)
hybridization patterns were observed: two red and two
reen signal remaining (B); and a dual fusion signal (C).
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Table 3 – Immunophenotyping, cytogenetic, ﬂuorescence in situ hybridization (FISH) and reverse transcription
polymerase chain reaction (RT-PCR) of infant acute myeloid leukemia cases with hemophagocytosis.
Case Immunophenotype Cytogenetics FISH (%) RT-PCRa Conclusion
1. CD33/CD13/CD14/CD11bpos 46, XX, der(16) t(16;?)(p13;?)35 37 Type-I MYST-CREBPP
2. CD34/CD33/CD13/CD4pos/CD14neg. 46, XY10 9 NT –
3. CD33CD33/CD13/CD14/CD11bneg NT 18 NEG MYST-CREBPP
4. CD33/CD13/CD7/CD117/CD56pos NT 10 NT MYST-CREBPP
5. CD34/CD33/CD13/CD14pos/CD15/CD16pos NT 34 NEG MYST-CREBPP
6. CD34/CD33/CD13posCD61/CD41a/CD42b/CD56pos NT 15 NEG MYST-CREBPP
7. CD34/CD33/CD13/CD117pos NT 6 NEG –
8. CD34/CD33/CD13/CD117/CD14neg 45, XY, t(8;8)(q21;1p25) 10 8 NT –
9. CD34/CD33/CD13, CD56 pos, CD61Neg 46, XY, 16H+12 6 NT –
10. NT NT 9 NEG –
11. CD42/CD61 NT 9 Type-I Undetermineda
–: Considered negative; NT: not tested; NEG: Negative.
a Undetermined because the FISH cut-off values were calculated as 6 ± 3% of fusion gene signals, and discordant result with the RT-PCR, the
type-I fragment length was not as expected.
Figure 3 – Agarose gel images of RT-PCR for MYST3-CREBBP fusion genes. Gel A, shows positive reactions for the
MYST3-CREBBP fusion gene. Samples 2 (A) and 19 (B) are the positive controls in each reaction. Sample 1 (A and B) is the
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6.
None of the eleven AML  cases presented with the RUNX1-
UNX1T1, CBFb-MYH11, BCR-ABL1, MLL-AFF1, MLL-MLLT1,
RAS, FLT3 or c-KIT mutations.
The patients received AML  treatment according to the BFM
ML-2004 protocol and only one out of ﬁve patients with the
ML  MYST3-CREBBP fusion gene is still alive.
iscussion
hromosomal abnormalities in childhood AML  are frequent;
he MYST3-CREBBP rearrangement, however, is not.1,17 Here,
e report for the ﬁrst time the presence of MYST3-CREBBP
earrangement in ﬁve out of eleven (36.4%) AML cases
ith hemophagocytosis found in a Brazilian i-AML cohort.
he morphological observation of hemophagocytosis was an
mportant variable for the selection criteria to investigate the
YST3-CREBBP fusion gene. Clinically, these cases appear to
ave distinct disease manifestations with skin nodules, CNS
nvolvement and chloroma.1,5,18 As pointed out by Hatano
t al., other chromosomal abnormalities in AML, such as
(16;21)(p11;q22), karyotypes involving the 8p11 breakpoint,
(8;19)(p11;q32), complex rearrangements and other chromo-
omal translocations are associated with the presence ofs #1 and #11. In gel B, all samples are negative for the
hemophagocytosis by blast cells.19 This supports our data
showing an absence of the MYST3-CREBBP fusion gene in four
cases in this study. According to the literature, in the major-
ity of patients described with myelomonocytic morphology,
the presence of CD56 cellular expression predicts an associa-
tion with hemophagocytosis and involvement of the leukemia
cutis.1,5,19–22
The technique used to identify this chromosomal alter-
ation was FISH because conventional karyotyping was not
always available. Failure to obtain mitosis was a pitfall. Multi-
color karyotyping technologies such as multicolor-FISH would
certainly elucidate such subtle chromosomal rearrangements
if mitosis were successfully obtained. Based on hematological
signs, we chose to carry out the FISH method followed by RT-
PCR as a laboratorial strategy to search for the MYST3-CREBBP
fusion gene. The FISH analysis showed a fusion signal above
the cutoff value for the speciﬁc MYST3 and CREBBP probes on
interphase nuclei, suggesting the presence of a MYST3-CREBBP
fusion chimera in ﬁve cases. This ﬁnding indicates a possible
generation of MYST3-CREBBP, since both chromosome regions
represented by the clones that contain the MYST3 and CREBBP
genes appeared co-localized. In one case, RT-PCR for the type
I fusion transcript followed by direct sequencing showed a
∼900 pb transcript probably related to an unspeciﬁc ampliﬁca-
tion. In the other four cases, no amplicon was observed. Type
I (MYST3 exon 16-CREBBP exon 3) is the most common form in
oter.
r
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adults with MYST3-CREBBP AML.16,23 Low expression or insta-
bility of the chimeric transcripts24 and RNA degradation might
explain the absence of ampliﬁcation by RT-PCR.
Recently, Panagopoulos et al. described an AML with
hemophagocytosis and with two translocations with break-
points that suggest other candidate genes different to MYST3
and CREBBP.25 They studied the patients’ leukemic cells not
only by karyotyping, FISH and RT-PCR, but also using the
modern RNA-seq technique and programs that are speciﬁc
for fusion genes. Interestingly, the techniques initially failed
to detect the biologically important MYST3-CREBBP fusion,
although it was manually retrievable from the raw sequenc-
ing data, suggesting that additional information about clinical,
morphological, and molecular cytogenetic features should be
taken into account when searching for newly described crucial
fusion genes in typical hematologic malignancies.25
One important point should be discussed is related
to AML-MYST3-CREBBP and the differential diagnosis of
a hemaphagocytic syndrome such as HLH, which is a
severe hyperinﬂammatory condition with clinical symp-
toms that include fever, cytopenias, hepatosplenomegaly, and
hemophagocytosis.26 However, this hemophagocytosis in BM
is morphological in benign macrophages. HLH, when occur-
ring in young children, is associated with inherited genetic
defects and diagnostic criteria combine both biological fea-
tures, including natural killer cell activity and high-soluble
interleukin-2-receptor levels.27
AML  cases younger than two years old with hemophago-
cytosis should be investigated for the presence of the
MYST3-CREBBP and other chromosomal alterations. In the I-
BFM AML  study group, more  than 50% of the MYST3-CREBBP
cases were found in infants and the frequency of congeni-
tal cases was signiﬁcantly higher.5 One of our cases described
herein was congenital leukemia. Some authors consider that
congenital AML-MYST3-CREBBP may be a self-limiting dis-
ease reaching spontaneous remission. A ‘watch-and-wait’
policy should be considered in congenital patients with mild
clinical symptoms provided that close long-term monitor-
ing is used.5,28–30 However, cases from our cohort suffered
from aggressive disease with dismal outcomes. Interestingly,
the genomic landscape of childhood AML-MYST3-CREBBP
has a speciﬁc signature clustered close to AML  with MLL
rearrangements.5,31,32 The similarity consists in the character-
istic pattern of up-regulation of HOXA9, HOXA10, and cofactor
MEIS1 and down-regulation of other homeobox family genes.32
The high frequency of AML-MYST3-CREBBP in infants (≤24
months) and congenital cases support the hypothesis that
leukemia occurs during the in utero life and as in the MLL
rearrangements model they should be explored for a better
understanding of AML  leukemogenesis.
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